| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| INCYTE CORP | Director | Common Stock | 7,389 | $449,620 | $60.85 | 10 Jun 2025 | Direct |
| Rubius Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 50,000 | 29 Jul 2022 | Direct | ||
| INCYTE CORP | Director | Non Qualfied Stock Option (right to buy) | 9,216 | 10 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| INCY | INCYTE CORP | 10 Jun 2025 | 3 | -$59,489 | 4 | Director | 12 Jun 2025, 16:28 |
| INCY | INCYTE CORP | 12 Jun 2024 | 3 | -$45,075 | 4 | Director | 14 Jun 2024, 12:15 |
| INCY | INCYTE CORP | 14 Jun 2023 | 3 | -$29,983 | 4 | Director | 16 Jun 2023, 16:00 |
| INCY | INCYTE CORP | 03 Oct 2022 | 2 | $0 | 4 | Director | 05 Oct 2022, 17:01 |
| INCY | INCYTE CORP | 01 Oct 2022 | 0 | $0 | 3 | Director | 05 Oct 2022, 16:03 |
| /report/000170940122000004-schaffert-susanne-2022-07-29 | Rubius Therapeutics, Inc. | 29 Jul 2022 | 1 | $0 | 4 | Director | 01 Aug 2022, 17:38 |
| /report/000170940122000002-schaffert-susanne-2022-07-12 | Rubius Therapeutics, Inc. | 12 Jul 2022 | 0 | $0 | 3 | Director | 19 Jul 2022, 17:54 |